Calton & Associates Inc. Buys New Holdings in Eli Lilly and Co (LLY)

Calton & Associates Inc. bought a new position in shares of Eli Lilly and Co (NYSE:LLY) during the 4th quarter, Holdings Channel reports. The firm bought 2,818 shares of the company’s stock, valued at approximately $237,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Acrospire Investment Management LLC lifted its holdings in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and during the 2nd quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and during the 2nd quarter worth about $129,000. Front Row Advisors LLC acquired a new position in shares of Eli Lilly and in the 4th quarter valued at about $137,000. Finally, Willingdon Wealth Management acquired a new position in shares of Eli Lilly and in the 3rd quarter valued at about $138,000. 76.45% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Co (NYSE:LLY) opened at $76.23 on Friday. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a market capitalization of $83,940.00, a PE ratio of -381.15, a P/E/G ratio of 1.41 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. During the same period in the previous year, the company posted $0.95 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. equities analysts anticipate that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.95%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently -1,040.00%.

LLY has been the topic of a number of recent analyst reports. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and boosted their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 5th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research note on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $92.02.

In related news, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold a total of 259,610 shares of company stock valued at $22,727,406 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/10/calton-associates-inc-buys-new-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit